IntegrateRNA Launches Custom Aminoacyl-tRNA Synthesis Service to Advance Protein Engineering Research
IntegrateRNA's new Aminoacyl-tRNA In Vitro Synthesis Service enables researchers to create custom proteins with non-canonical amino acids, potentially accelerating drug discovery and biotechnology development.
IntegrateRNA, the R&D focused business division of Creative Biogene, has launched its Aminoacyl-tRNA In Vitro Synthesis Service, providing researchers with tools to generate customized aminoacylated tRNAs for advanced protein synthesis applications. This service represents a significant advancement in protein engineering capabilities, enabling the production of non-canonical amino acid-containing proteins with enhanced functional characteristics.
The technology utilizes a robust in vitro translation system to covalently link amino acids to transfer RNA molecules through an enzyme-based process that mimics natural cellular translation. This approach supports high-yield production of aminoacylated tRNAs and facilitates the inclusion of non-canonical or modified amino acids, expanding the design possibilities for researchers developing novel proteins with improved stability, activity, or specificity.
Marcia Brady, Head of Technology at Creative Biogene, emphasized the transformative potential of this development, stating that synthesizing proteins with non-canonical amino acids opens new possibilities for designing proteins with specific properties and could significantly accelerate biotechnology development. The service is expected to find applications across multiple industries including synthetic biology, drug discovery, enzyme engineering, pharmaceutical R&D, and novel biologics development.
Researchers can now create protein variants with unique properties that may not be achievable through natural processes alone, particularly in developing new therapeutics or industrial enzymes. The technology's ability to insert non-standard amino acids into proteins provides scientists with unprecedented control over protein design and function.
Looking ahead, IntegrateRNA plans to enhance its Aminoacyl-tRNA synthesis platform by supporting an even broader array of amino acid modifications and scaling production to industrial levels. These advancements could have major implications for synthetic biology and therapeutic protein development, potentially leading to next-generation biopharmaceuticals and engineered enzymes that address complex medical and industrial challenges.
The service builds on IntegrateRNA's position as a trusted supplier of high-quality oligonucleotides and custom RNA synthesis services, supporting cutting-edge research in molecular biology and therapeutic development across academic, pharmaceutical, and biotechnology sectors. This innovation addresses the growing need for more precise and scalable protein synthesis methods in research and development environments.